Home › Companies › CGON

CG Oncology

CGON Lead: NDA Submitted 5 Biotech Distilled articles ↓

Oncology Gene Therapy

Most recent annual filing: 2026-02-15

Pipeline (1 active programs)

cretostimogene grenadenorepvec

Gene Therapy Target: Rb-E2F pathway, GM-CSF

Non-Muscle Invasive Bladder Cancer NDA Submitted intravesical Merck

Biotech Distilled coverage (5)

2026-05-26 UPDATE: CG Oncology (CGON) — The COO Walks, the CEO Doubles Up 🔒 Paid
2026-05-16 UPDATE: CG Oncology (CGON) — The Gem Combo Clears the Bar 🔒 Paid
2026-05-09 UPDATE: CG Oncology (CGON) — Q1 2026 Status Check 🔒 Paid
2026-02-28 UPDATE: CG Oncology (CGON) - EoY Update 🔒 Paid
2026-01-23 CG Oncology (CGON): Scientific Deep Dive for Creto and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.